Gapping down
In reaction to earnings/guidance:
- EAT -6.8% (guidance), NDSN -1.2%,
Other news:
- VTVT -32.7% (reports topline results of Phase 2 Elevage study of Azeliragon; did not meet primary endpoint)
- MRAM -16.2% (CEO to resign, reduces higher end of Q4 rev guidance range)
- GLPG -15% (GILD and GLPG amend commercialization deal for Jyseleca; will not advance Jyseleca for Rheumatoid Arthritis in US)
- IQ -9.5% (commences convertible notes offering and 40 mln ADSs; also files for mixed securities shelf offering)
- PEN -8.1% (voluntarily recalls all configurations of JET 7 Reperfusion Catheter with Xtra Flex technology)
- GLSI -6.4% (stock offering
- SHSP -5% (stock offering)
- DISH -4.7% ($2 bln convertible notes offering)
- NFE -3% (stock offering)
- PHAT -2.5% (stock offering)
- NOK -2.2% (provides update on its operating model)
- CSTL -2% (prices offering of 4 mln shares of common stock at $58.00 per share)
- UIHC -1.9% (announces estimated Q4 catastrophe losses)
- WPG -1.9% (entered into confidentiality agreement in connection with discussions with certain of debt holders with respect to potential strategic or capital markets transactions to enhance the capital structure)
Analyst comments:
- MRNA -2.7% (downgraded to Equal-Weight from Overweight at Morgan Stanley; downgraded to Hold from Buy at Jefferies)
- ETSY -2% (downgraded to Hold from Buy at Stifel)
- SAVE -1.7% (downgraded to Underweight from Overweight at JP Morgan)
- JBLU -1.5% (downgraded to Underweight from Overweight at JP Morgan)
- SPOT -1.5% (downgraded to Neutral from Outperform at Credit Suisse)
- UAL -1.5% (downgraded to Underweight from Overweight at JP Morgan)
- AAXN -1.4% (downgraded to Mkt Perform from Mkt Outperform at JMP Securities)
- EA -1.1% (downgraded to Neutral from Overweight at JP Morgan)
- FIT -0.6% (downgraded to Underweight from Equal-Weight at Morgan Stanley),